A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 833 participants.

Also called NCT01849289

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 833 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01849289
Main results
  • A Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naïve Patients with Type 2 Diabetes Mellitus Drugs in R&D, 2016-06 DOI, PubMed 27098525, PMC4875929 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Brazil, Canada, China, Romania, South Africa, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01849289. Randomized; no masking; primary purpose treatment. Start 2013-06-02 (actual); primary completion 2014-05-15 (actual). Results posted on 2016-01-14.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes
Acronym
BEGIN™
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Insulin Degludec
Intervention (Drug)
Insulin Glargine
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct01849289
Content hash
99eed1e9288153e7546c5e74f609cb49584d120adf0c313d4cd5a6674e226fc5